Telavancin: A Novel Semisynthetic Lipoglycopeptide Agent to Counter the Challenge of Resistant Gram-Positive Pathogens

Therapeutic Advances in Infectious Disease
doi 10.1177/2049936117690501
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SAGE Publications


Related search